



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. AM100056 D1)

In re Patent Application of:) Appln. No.: 10/618,044
DAN M. BERGER *et al.*) Confirmation No.: 4109
Filed: 07/10/2003) Customer No.: 25291
For: TRICYCLIC PROTEIN) Group Art Unit: 1626
KINASE INHIBITORS) Examiner: Ebenezer O. Sackey
) Paper No.: 11
)

AMENDMENT

Dear Sir:

Responsive to the Office communication mailed October 1, 2004 in the above-referenced patent application, please amend the above-referenced application using the below instructions.

INTRODUCTORY COMMENTS

In accord with the requirements of 37 C.F.R. § 1.121, the amendment to the claims and a complete listing of all pending claims in the application begin on a separate sheet to facilitate separate indexing and electronic scanning of each part of the amendment document for placement in an e-file wrapper. As required, only the claim number and status indicate the canceled claims. For the convenience of the Office staff, the amendment is placed in the below Appendix and incorporated herein by reference thereto.

The present amendment is presented to the Examiner to respond directly to the Office action of October 1, 2004 in a good faith attempt to place the application in condition for an allowance. Except as noted below, the nonelected invention has been canceled from the pending claims. Obvious typographical or clerical errors have also been corrected. Support for changing "ECK/LERK-1" to *Mek-Erk* in Claim 28 finds support on pages 127-130 of the specification. No new matter is being introduced into the application by this amendment.